Oncotrap Inc.
Chapel Hill, NC
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1168 Legend Oaks Dr, Chapel Hill, NC 27517, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Novab, Inc. | Tucker, GA | 621511 Medical Laboratories |
| Larix Bioscience LLC | Sunnyvale, CA | — |
| Abzyme Therapeutics LLC | Pottstown, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Avantgen Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Sapience Therapeutics, Inc. | Tarrytown, NY | — |
About the company
Oncotrap Inc. is a corporate entity registered to receive federal awards from the U.S. government. Based on the awarded grants, Oncotrap specializes in developing innovative therapeutic biologics and drug delivery platforms for the treatment of cancer, liver diseases, and infectious diseases.
Oncotrap has received several federal grants from the National Institutes of Health (NIH) to pursue research projects in these areas. A $400,000 grant from the National Cancer Institute supported the development of an aptamer-directed IgG1-Fc drug conjugate platform for treating pancreatic ductal adenocarcinoma. Another $361,400 grant from the National Institute of Diabetes and Digestive and Kidney Diseases funded research on a bispecific single-domain antibody targeting chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis. Additionally, a $299,128 grant from the National Institute of Allergy and Infectious Diseases supported the creation of an mRNA-delivered single-domain antibody library for combinatorial deciphering of therapeutic targets for COVID-19 related cytokine release syndrome. These grants demonstrate Oncotrap's expertise in antibody and aptamer-based therapeutics, drug conjugates, and mRNA delivery platforms for various disease areas, including cancer, liver diseases, and infectious diseases.
Quick answers
Is Oncotrap Inc. registered in SAM.gov?
Yes. Oncotrap Inc.'s SAM.gov registration is active through February 28, 2027.
What is Oncotrap Inc.'s CAGE code?
Oncotrap Inc.'s CAGE code is 7PVZ5, and its Unique Entity ID (UEI) is KX22VNNMBYZ3.
What is Oncotrap Inc.'s most recent federal award?
Oncotrap Inc.'s most recent federal grant award is An aptamer-directed IGG1-FC drug conjugate (AFDC) for treating pancreatic cancer (R43CA281460), from National Cancer Institute (NIH), on September 22, 2023.
On GovTribe
See Oncotrap Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors